118 related articles for article (PubMed ID: 83018)
21. Thyroid xenografts from patients with Graves' disease in severe combined immunodeficient mice and NIH-beige-nude-xid mice.
Mukuta T; Arreaza G; Nishikawa M; Resetkova E; Jamieson C; Tamai H; Volpé R
Clin Invest Med; 1997 Feb; 20(1):5-15. PubMed ID: 9013039
[TBL] [Abstract][Full Text] [Related]
22. Failure to demonstrate cell-mediated immune responses to thyroid antigens in Graves' disease using in vitro assays of lymphokine-mediated migration inhibition.
Ludgate ME; Ratanachaiyavong S; Weetman AP; Hall R; McGregor AM
J Clin Endocrinol Metab; 1985 Jan; 60(1):98-102. PubMed ID: 3871093
[TBL] [Abstract][Full Text] [Related]
23. HLA and Graves' disease: an association with HLA-DRw3.
Allannic H; Fauchet R; Lorcy Y; Heim J; Gueguen M; Leguerrier AM; Genetet B
J Clin Endocrinol Metab; 1980 Oct; 51(4):863-7. PubMed ID: 6932402
[TBL] [Abstract][Full Text] [Related]
24. The role of HLA antigens in the manifestation and course of Graves' disease.
Stenszky V; Kozma L; Balazś C; Bear JC; Farid NR
Mol Biol Med; 1986 Feb; 3(1):53-62. PubMed ID: 3485758
[TBL] [Abstract][Full Text] [Related]
25. Human lymphocyte antigens in Graves' disease: correlation with persistent course of disease.
Baldini M; Pappalettera M; Lecchi L; Orsatti A; Meroni L; Tozzi R; Scalamogna M; Cantalamessa L
Am J Med Sci; 1995 Jan; 309(1):43-8. PubMed ID: 7825652
[TBL] [Abstract][Full Text] [Related]
26. Association of HLA antigen and restriction fragment length polymorphism of T cell receptor beta-chain gene with Graves' disease and Hashimoto's thyroiditis.
Ito M; Tanimoto M; Kamura H; Yoneda M; Morishima Y; Yamauchi K; Itatsu T; Takatsuki K; Saito H
J Clin Endocrinol Metab; 1989 Jul; 69(1):100-4. PubMed ID: 2567295
[TBL] [Abstract][Full Text] [Related]
27. Kappa/lambda immunoglobulin distribution in Graves' thyroid-stimulating antibodies. Simultaneous analysis of C lambda gene polymorphisms.
Williams RC; Marshall NJ; Kilpatrick K; Montano J; Brickell PM; Goodall M; Ealey PA; Shine B; Weetman AP; Craig RK
J Clin Invest; 1988 Oct; 82(4):1306-12. PubMed ID: 2902107
[TBL] [Abstract][Full Text] [Related]
28. HLA-DR associations with Graves' disease in eastern Hungary.
Stenszky V; Kozma L; Balazs C; Farid NR
Clin Invest Med; 1983; 6(3):181-4. PubMed ID: 6580983
[TBL] [Abstract][Full Text] [Related]
29. HLA-DR3 and HLA-DR5 associated thyrotoxicosis--two different types of toxic diffuse goiter.
Schleusener H; Schernthaner G; Mayr WR; Kotulla P; Bogner U; Finke R; Meinhold H; Koppenhagen K; Wenzel KW
J Clin Endocrinol Metab; 1983 Apr; 56(4):781-5. PubMed ID: 6131902
[TBL] [Abstract][Full Text] [Related]
30. TSH-receptor antibodies, HLA B8 and thyroid autoantibodies in patients with Graves' disease in therapeutically induced euthyroidism.
Schernthaner G; Ludwig H; Schleusener H; Finke R; Kotulla P; Mayr WR
Experientia; 1979 Oct; 35(10):1408-9. PubMed ID: 227717
[TBL] [Abstract][Full Text] [Related]
31. Linkage of HLA-DR beta specific restriction fragment length polymorphisms with Graves' disease.
Boehm BO; Schifferdecker E; Kuehnl P; Schöffling K
Acta Endocrinol (Copenh); 1988 Oct; 119(2):251-6. PubMed ID: 2902722
[TBL] [Abstract][Full Text] [Related]
32. Analysis of linkage between HLA haplotype and susceptibility to Graves' disease in multiple-case Chinese families in Hong Kong.
Hawkins BR; Ma JT; Lam KS; Wang CC; Yeung RT
Acta Endocrinol (Copenh); 1985 Sep; 110(1):66-9. PubMed ID: 3839962
[TBL] [Abstract][Full Text] [Related]
33. Immunogenetics of Graves' ophthalmopathy.
Weetman AP; So AK; Warner CA; Foroni L; Fells P; Shine B
Clin Endocrinol (Oxf); 1988 Jun; 28(6):619-28. PubMed ID: 2908181
[TBL] [Abstract][Full Text] [Related]
34. Prediction of remission after antithyroid drug treatment in Graves' disease.
Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
[TBL] [Abstract][Full Text] [Related]
35. Class III alleles and high-risk MHC haplotypes in type I diabetes mellitus, Graves' disease and Hashimoto's thyroiditis.
Skanes VM; Barnard J; Farid N; Marshall WH; Murphy L; Rideout D; Taylor R; Xidos G; Larsen B
Mol Biol Med; 1986 Apr; 3(2):143-57. PubMed ID: 3461234
[TBL] [Abstract][Full Text] [Related]
36. Polymorphism of the fourth component of complement in Graves' disease and type I diabetes mellitus.
Skanes V; Larsen B; Sampson-Murphy L; Farid NR
Clin Invest Med; 1985; 8(2):126-32. PubMed ID: 3869086
[TBL] [Abstract][Full Text] [Related]
37. Molecular analysis of stimulatory anti-thyrotropin receptor antibodies (TSAbs) involved in Graves' disease. Isolation and reconstruction of antibody genes, and production of monoclonal TSAbs.
Akamizu T; Matsuda F; Okuda J; Li H; Kanda H; Watanabe T; Honjo T; Mori T
J Immunol; 1996 Oct; 157(7):3148-52. PubMed ID: 8816426
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous assay of thyroid adenylate cyclase- and growth-stimulating antibodies using FRTL-5 cells. Evidence suggesting their identity in patients with Graves' disease.
Marcocci C; Vitti P; Lopez G; Santini F; Mammoli C; Fenzi GF; Pinchera A
Clin Endocrinol (Oxf); 1989 Feb; 30(2):109-19. PubMed ID: 2575468
[TBL] [Abstract][Full Text] [Related]
39. Two major genes, linked to HLA and Gm, control susceptibility to Graves' disease.
Farid NR; Bear JC
Nature; 1982 Feb; 295(5850):629. PubMed ID: 6895778
[No Abstract] [Full Text] [Related]
40. Tumor necrosis factor beta gene polymorphisms in Graves' disease.
Badenhoop K; Schwarz G; Schleusener H; Weetman AP; Recks S; Peters H; Bottazzo GF; Usadel KH
J Clin Endocrinol Metab; 1992 Feb; 74(2):287-91. PubMed ID: 1346144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
